Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 13 of the 27 sources its claims cite were checked for support.

Last-mile delivery increases vaccine uptake in Sierra Leone

Open access

Published version of a preprint

Abstract

Abstract Less than 30% of people in Africa received a dose of the COVID-19 vaccine even 18 months after vaccine development 1 . Here, motivated by the observation that residents of remote, rural areas of Sierra Leone faced severe access difficulties 2 , we conducted an intervention with last-mile delivery of doses and health professionals to the most inaccessible areas, along with community mobilization. A cluster randomized controlled trial in 150 communities showed that this intervention with mobile vaccination teams increased the immunization rate by about 26 percentage points within 48–72 h. Moreover, auxiliary populations visited our community vaccination points, which more than doubled the number of inoculations administered. The additional people vaccinated per intervention site translated to an implementation cost of US $33 per person vaccinated. Transportation to reach remote villages accounted for a large share of total intervention costs. Therefore, bundling multiple maternal and child health interventions in the same visit would further reduce costs per person treated. Current research on vaccine delivery maintains a large focus on individual behavioural issues such as hesitancy. Our study demonstrates that prioritizing mobile services to overcome access difficulties faced by remote populations in developing countries can generate increased returns in terms of uptake of health services 3 .

Overview

CoChat Summary

TL;DR

A pre-registered cluster randomized controlled trial in 150 rural Sierra Leone communities found that bringing vaccines and health workers to remote villages, plus community mobilization, increased verified adult COVID-19 vaccination by about 26 percentage points within 48–72 hours. The intervention also drew in additional people from nearby areas, more than doubling vaccination counts, at an implementation cost of about US $33 per person vaccinated.

Key findings

  • In 150 communities, the intent-to-treat effect on adult vaccination was 26 percentage points (OLS, P < 0.001, n = 12,096); the text says vaccination rose from 6.2% in control villages to 30.2% in treatment villages.
  • The number of vaccinated people per treatment site increased from about 9 pre-intervention to about 55 during the 2–3 day intervention window, a 6-fold increase.
  • The paper reports that 53% of vaccinated people not captured in the census were visitors from nearby villages, with the remaining 47% being returnees, commuters, or others not in the census.
  • The intervention cost was US $33 per person vaccinated; the total cost to reach 100 villages was $156,023.5 (about $1,560 per village), and the authors estimate this would approach $23 per person vaccinated at larger scale.
  • Heterogeneity: the treatment effect was 7 percentage points larger for men than women and 12 percentage points larger for people >55 than those aged 18–24; no detectable differences were found by education, land ownership, or food security.

Methods

  • Design: Pre-registered cluster randomized controlled trial in 150 rural villages in Sierra Leone, with 100 intervention and 50 control communities; intervention villages received mobile vaccination teams plus community mobilization, and treatment villages were further split into door-to-door and small-group outreach.
  • Sample/data: Villages were drawn from remote communities outside the 5-mile PHU catchment area; the census covered 29,588 individuals across the 150 villages, and the baseline survey included 2,240 respondents.
  • Analysis: Main impacts were estimated with OLS intent-to-treat models with randomization-block fixed effects and village-clustered robust standard errors; the paper also analyzes village-level vaccination counts, knowledge/trust outcomes in a 45-village subsample, and subgroup heterogeneity.

Limitations

  • The paper states that the $33 cost per vaccinated person varied substantially across villages because vaccination rates ranged from 0 to 69%.
  • The authors note that 2 of the 100 treatment villages did not allow the intervention, which inflates the overall average cost.
  • They report large cross-team variation in performance; some teams administered more than twice as many vaccines as others.
  • Evident from the text: the study’s primary vaccination-rate outcome is measured over a short 48–72 hour window, so the paper does not establish long-term persistence of uptake.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41586-024-07158-w

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Procedure of vaccination team visits. a–f, Representative photographs of the steps taken by the vaccination teams in each village for the mobile vaccination clinic. a, Step 1. A social mobilization team from the MoHS organizes a meeting with village leaders. b, Step 2. Social mobilizers convene a community meeting to talk directly with all village residents about vaccine efficacy and safety, the importance of getting vaccinated, address villagers’ questions and concerns, and the location and timing of the mobile vaccination site. c, Step 3. MoHS staff bring vaccine doses and staff to the village. d, Step 4. MoHS staff set up a 48–72 h mobile vaccine clinic in a central location in the village. e, Step 5a. Social mobilizers provide vaccine information to community members in private during door-to-door visits. f, Step 5b. Social mobilizers target social groups at fixed spots in and around the villages. Photographs in a–f reproduced with permission from Concern Worldwide.
Fig. 1 Procedure of vaccination team visits. a–f, Representative photographs of the steps taken by the vaccination teams in each village for the mobile vaccination clinic. a, Step 1. A social mobilization team from the MoHS organizes a meeting with village leaders. b, Step 2. Social mobilizers convene a community meeting to talk directly with all village residents about vaccine efficacy and safety, the importance of getting vaccinated, address villagers’ questions and concerns, and the location and timing of the mobile vaccination site. c, Step 3. MoHS staff bring vaccine doses and staff to the village. d, Step 4. MoHS staff set up a 48–72 h mobile vaccine clinic in a central location in the village. e, Step 5a. Social mobilizers provide vaccine information to community members in private during door-to-door visits. f, Step 5b. Social mobilizers target social groups at fixed spots in and around the villages. Photographs in a–f reproduced with permission from Concern Worldwide.CC BY · PubMed Central
Fig. 2 Vaccination rate among adults enumerated during the census before and after mobile vaccination programme. The proportion of vaccinated adults that were enumerated during the census before and at the end of the study in control villages and pooled treatment villages. The analysis includes the 12,096 people (aged >18 years) in 150 villages. Data are presented as the mean ± s.e.m. In the control group, 6% were vaccinated at baseline, whereas 9.5% were vaccinated in treatment groups. At endline, 30% were vaccinated. The intent-to-treat treatment effects estimated using OLS and including randomization block fixed effects and heteroscedasticity-robust standard errors clustered at the village level are provided in Extended Data Table 3.
Fig. 2 Vaccination rate among adults enumerated during the census before and after mobile vaccination programme. The proportion of vaccinated adults that were enumerated during the census before and at the end of the study in control villages and pooled treatment villages. The analysis includes the 12,096 people (aged >18 years) in 150 villages. Data are presented as the mean ± s.e.m. In the control group, 6% were vaccinated at baseline, whereas 9.5% were vaccinated in treatment groups. At endline, 30% were vaccinated. The intent-to-treat treatment effects estimated using OLS and including randomization block fixed effects and heteroscedasticity-robust standard errors clustered at the village level are provided in Extended Data Table 3.CC BY · PubMed Central
Fig. 3 Count of people vaccinated per site before and after the mobile vaccination programme. The number of the people vaccinated before and by the end of the study. Data are presented as the mean ± s.e.m. The analysis includes 150 villages. In the control group, on average five people were vaccinated, whereas in treatment villages, this was nine people. Treatment increased the count to 55 people, including 22–23 individuals who were enumerated during the census group, 12–13 people from nearby villages and 11–12 short-term, circular commuters or migrant returnees who were not present on the day of the census and could not be matched to our listing records, as well as individuals whose community of origin was unknown. The intent-to-treat treatment effects estimated using OLS and including randomization block fixed effects and heteroscedasticity-robust standard errors are provided in Extended Data Table 4.
Fig. 3 Count of people vaccinated per site before and after the mobile vaccination programme. The number of the people vaccinated before and by the end of the study. Data are presented as the mean ± s.e.m. The analysis includes 150 villages. In the control group, on average five people were vaccinated, whereas in treatment villages, this was nine people. Treatment increased the count to 55 people, including 22–23 individuals who were enumerated during the census group, 12–13 people from nearby villages and 11–12 short-term, circular commuters or migrant returnees who were not present on the day of the census and could not be matched to our listing records, as well as individuals whose community of origin was unknown. The intent-to-treat treatment effects estimated using OLS and including randomization block fixed effects and heteroscedasticity-robust standard errors are provided in Extended Data Table 4.CC BY · PubMed Central
Fig. 4 Effect of pooled treatment on knowledge and attitudes among adults enumerated during census. Intent-to-treat estimates of community treatment assignment for each outcome listed on the y axis. Treatment effects were estimated using OLS and included randomization block fixed effects and heteroscedasticity-robust standard errors clustered at the village level. Each dot is labelled with the exact coefficient (to three decimal places) and significance at the ***1,**5 and *10 per cent critical level. Bars represent 95% CIs of treatment estimates. The analysis includes 45 villages and 817 households surveyed at endline for which we observed complete randomization blocks. Associated regression results are provided in Extended Data Tables 6 and 7, including corresponding sample sizes. Reported estimates do not correct for multiple hypothesis testing. The Extended Data tables report the associated FDR-adjusted q values. The survey measures for the ‘Believes COVID-19 is real’ comes from the survey question: “Do you believe that COVID-19 exists in the world?” (yes or no). ‘Knows about the COVID-19 vaccine’ comes from the survey question: “Do you know about the COVID-19 vaccine/marklate?” (yes or no). ‘Vaccines are effective’ is 1 if respondents completely agree with the statement: “Vaccines are effective.” ‘Vaccines are safe’ is 1 if respondents completely agree with the statement “How much do you agree with this statement: vaccines are safe.” Trust in sources of information are from a multiple-select question: “Who do you most trust getting information about COVID-19?” (community health clinic (CHC), MoHS, media (news, TV), social media (Facebook, among others), family and friends, among others).
Fig. 4 Effect of pooled treatment on knowledge and attitudes among adults enumerated during census. Intent-to-treat estimates of community treatment assignment for each outcome listed on the y axis. Treatment effects were estimated using OLS and included randomization block fixed effects and heteroscedasticity-robust standard errors clustered at the village level. Each dot is labelled with the exact coefficient (to three decimal places) and significance at the ***1,**5 and *10 per cent critical level. Bars represent 95% CIs of treatment estimates. The analysis includes 45 villages and 817 households surveyed at endline for which we observed complete randomization blocks. Associated regression results are provided in Extended Data Tables 6 and 7, including corresponding sample sizes. Reported estimates do not correct for multiple hypothesis testing. The Extended Data tables report the associated FDR-adjusted q values. The survey measures for the ‘Believes COVID-19 is real’ comes from the survey question: “Do you believe that COVID-19 exists in the world?” (yes or no). ‘Knows about the COVID-19 vaccine’ comes from the survey question: “Do you know about the COVID-19 vaccine/marklate?” (yes or no). ‘Vaccines are effective’ is 1 if respondents completely agree with the statement: “Vaccines are effective.” ‘Vaccines are safe’ is 1 if respondents completely agree with the statement “How much do you agree with this statement: vaccines are safe.” Trust in sources of information are from a multiple-select question: “Who do you most trust getting information about COVID-19?” (community health clinic (CHC), MoHS, media (news, TV), social media (Facebook, among others), family and friends, among others).CC BY · PubMed Central
Fig. 5 Effect of pooled treatment by respondent characteristics among those enumerated during census. Intent-to-treat estimates of the vaccination rate of the pooled treatment groups for each subgroup listed on the y axis. Treatment effects were estimated using OLS and included randomization block fixed effects and heteroscedasticity-robust standard errors clustered at the village level. Each dot is labelled with the exact coefficient (to three decimal places) and significance at the ***1, **5 and *10 per cent critical level. Bars represent 95% CIs of treatment estimates. The dependent variable is the vaccination status of adults at the end of the study enumerated during the census. Sex, age and schooling data are from the census. Land ownership and food insecurity are from the baseline sample. Associated treatment estimates and associated sample size for each subgroup are provided in Extended Data Table 8. The indicator for ‘HH head any schooling’ indicates whether the household (HH) head had schooling above the primary level. The ‘HH owns any land’ indicates whether the household owns land. The ‘reduced portions of food’ statements indicate whether any household member had reduced food portions during the previous week.
Fig. 5 Effect of pooled treatment by respondent characteristics among those enumerated during census. Intent-to-treat estimates of the vaccination rate of the pooled treatment groups for each subgroup listed on the y axis. Treatment effects were estimated using OLS and included randomization block fixed effects and heteroscedasticity-robust standard errors clustered at the village level. Each dot is labelled with the exact coefficient (to three decimal places) and significance at the ***1, **5 and *10 per cent critical level. Bars represent 95% CIs of treatment estimates. The dependent variable is the vaccination status of adults at the end of the study enumerated during the census. Sex, age and schooling data are from the census. Land ownership and food insecurity are from the baseline sample. Associated treatment estimates and associated sample size for each subgroup are provided in Extended Data Table 8. The indicator for ‘HH head any schooling’ indicates whether the household (HH) head had schooling above the primary level. The ‘HH owns any land’ indicates whether the household owns land. The ‘reduced portions of food’ statements indicate whether any household member had reduced food portions during the previous week.CC BY · PubMed Central
Fig. 6 Cost per person vaccinated compared with other studies. The cost per vaccination administered (in year 2000 US dollars, calculated using inflation data sourced from the US Bureau of Labor Statistics). These are treatments from studies included in Supplementary Table 2 that explicitly provided information about the cost of the intervention per vaccine actually administered. This cost specifically refers to the intervention and does not include the cost of the vaccine itself. Studies that did not unequivocally state the cost of the intervention per vaccinated person were not included. The colour of each bar indicates the broad type of intervention. The cost per person vaccinated in our study was $32.70, which is approximately $19.27 in 2000 US dollars. The mean value in this figure is $83 (s.d. = 132) after excluding the most expensive approach. References 23,28,31–48 are cited in this figure.
Fig. 6 Cost per person vaccinated compared with other studies. The cost per vaccination administered (in year 2000 US dollars, calculated using inflation data sourced from the US Bureau of Labor Statistics). These are treatments from studies included in Supplementary Table 2 that explicitly provided information about the cost of the intervention per vaccine actually administered. This cost specifically refers to the intervention and does not include the cost of the vaccine itself. Studies that did not unequivocally state the cost of the intervention per vaccinated person were not included. The colour of each bar indicates the broad type of intervention. The cost per person vaccinated in our study was $32.70, which is approximately $19.27 in 2000 US dollars. The mean value in this figure is $83 (s.d. = 132) after excluding the most expensive approach. References 23,28,31–48 are cited in this figure.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 2 Not valid · 9 Not checked · 135 Own results and interpretations

53 more claims

Create a free account to see all 156 claims and to verify the 11 references still open.

See all claims — free account
  • Probably not a substantial claim. 69
  • It may state two separate claims as one. 48
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 52 references

Research works printed but not linked: 2

  1. Herrett, E. et al. Text messaging reminders for influenza vaccine in primary care: a cluster randomised controlled trial (TXT4FLUJAB). BMJ Open 6, e010069 (2016). · DOI
  2. Yue, M. et al. Optimal design of population-level financial incentives of influenza vaccination for the elderly. Value Health 23, 200–208 (2020). · DOI

Cited by

See all 36

Metadata

Authors
Meriggi, N. F., Voors, M., Levine, M., Ramakrishna, V., Kangbai, D. M., Rozelle, M., Tyler, E., Kallon, S., Nabieu, J., Cundy, S., & Mobarak, A. M.
Affiliations
  • University of Oxford (GB)
  • Wageningen University & Research (NL)
  • University of Illinois Urbana-Champaign (US)
  • Boston University (US)
  • Ministry of Health and Sanitation (SL)
  • University of Sierra Leone (SL)
  • Yale University (US)
Corresponding author
  • Meriggi, Niccolò F.
  • Mobarak, Ahmed Mushfiq
Venue
Nature
Published
2024-03-13
Volume
627
Issue
8004
Pages
612-619
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4392747566
Cited by
36
References
52
Citations by year
2026: 11 · 2025: 14 · 2024: 7
FWCI
14.44
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed (publishedVersion)
  • Socio-Environmental Systems Modeling (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • Yale University
  • International Growth Centre
  • UK Research and Innovation
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (VI.Vidi.191.154, 21148)
Topics
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Health Sciences › Health Professions › General Health Professions › Health Policy Implementation Science
  • Social Sciences › Health › Public Health and Social Inequalities
Keywords
last-mile delivery, COVID-19 vaccination, vaccine uptake, mobile vaccination teams, rural healthcare access, community mobilization, vaccination coverage, implementation costs, transportation costs, Sierra Leone
MeSH terms
Vaccination Coverage, COVID-19, COVID-19 Vaccines, Vaccination Hesitancy, Adult, Child, Community Health Services, Female, Humans, Mobile Health Units, Mothers, Sierra Leone, Transportation, Rural Health Services, Mass Vaccination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Last-mile delivery increases vaccine uptake in Sierra Leone. https://app.cochat.ai/papers/10.1038/s41586-024-07158-w
The paper
Meriggi, N. F., Voors, M., Levine, M., Ramakrishna, V., Kangbai, D. M., Rozelle, M., Tyler, E., Kallon, S., Nabieu, J., Cundy, S., & Mobarak, A. M. (2024). Last-mile delivery increases vaccine uptake in Sierra Leone. Nature. https://doi.org/10.1038/s41586-024-07158-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.